BioNTech Names Guido Oelkers as CEO

Editor’s take: Guido Oelkers, Ph.D. takes the helm to diversify BioNTech’s portfolio and advance the company’s late-stage oncology assets, while co-founders, ​Ugur Sahin ​and ⁠Oezlem Tuereci look to pursue other opportunities.

Following an announcement in March that BioNTech’s co-founders, ​Ugur Sahin, Chief Executive Officer, ​and ⁠Oezlem Tuereci, Chief Medical Officer, would ​leave the company by the end of the year, BioNTech has appointed Guido Oelkers, Ph.D., as Chief Executive Officer, effective February 1, 2027. 

Oelker joins the company from the global biopharma company Swedish Orphan Biovitrum (Sobi), where he has served as CEO since 2017. Guido Oelkers brings more than 30 years of experience in the biotechnology and pharmaceutical industries. He has scaled global organizations, driving growth through focused capital allocation and operational excellence. Throughout his career, Guido Oelkers has successfully built innovative product portfolios across multiple areas, including oncology and immunology, while driving strong global business operations in key markets, namely in the U.S.

“BioNTech is in a pivotal phase as the Company focuses on advancing its diversified pipeline into approved products. I have come to know Guido Oelkers as a leader who combines a deep understanding of the pharmaceutical industry and strong strategic acumen with genuine respect for the culture and people of our organization,” said Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech. “With Guido Oelkers taking over, I feel confident that BioNTech is in a strong position to realize its vision. To ensure a smooth and successful handover, I will be actively supporting his onboarding.”

“BioNTech stands out through its scientific foundation and particularly its strong late-stage oncology pipeline,” said Guido Oelkers, Ph.D., designated CEO of BioNTech. “I am deeply honored to be leading BioNTech and prioritizing its evolution into a global biopharmaceutical company with multiple approved products by 2030, while continuing to advance its innovative pre-clinical and clinical portfolio in line with the Company’s strategy. I look forward to joining my colleagues on the Management Board and our teams worldwide on the journey ahead to deliver on BioNTech’s patient-centric strategy and create sustainable, long-term value.”